Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004915898> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W3004915898 endingPage "79" @default.
- W3004915898 startingPage "79" @default.
- W3004915898 abstract "79 Background: The Metabotropic Glutamate Receptor 1 (GRM1) is overexpressed in many solid tumors. It activates MAPK and PI3K/AKT pathways and promotes an immune-suppressive tumor microenvironment. In an immunocompetent melanoma mouse model, GRM1 blockade using riluzole or its pro-drug troriluzole (BHV-4157) and PD-1 blockade inhibit tumor growth in an additive manner. We conducted a phase Ib trial of troriluzole and the PD-1 antibody nivolumab. Methods: Patients with advanced or refractory solid tumors were treated with increasing doses of troriluzole. Troriluzole monotherapy was given for a 14-day lead-in period and then patients received troriluzole in combination with nivolumab 240 mg IV every 2 weeks. Results: We enrolled 14 patients with advanced solid tumors (melanoma=3, NSCLC=3, renal cell cancer=2, NSCLC=2, head and neck cancer=2). Eleven patients had prior therapy with anti-PD-(L)1. PK sampling demonstrated that the prodrug was cleaved efficiently without regard to food (Table). The most common TEAEs (all grades) occurring in >40% of patients were transaminitis, increased lipase and nausea. DLT occurred in 3 patients: 1) grade 3 anorexia, 2) grade 3 fatigue and, 3) atrial fibrillation. The MTD was determined to be troriluzole 140 mg QAM + 280 mg PO QHS. The response rate was 7 % (1/14); this occurred in a PD-L1 treated patient. The 6-month PFS rate was 21%. Correlative studies will be presented. Conclusions: The combination of troriluzole and nivolumab was safe and well-tolerated in this highly PD-1 refractory population. Clinical trial information: NCT03229278. [Table: see text]" @default.
- W3004915898 created "2020-02-14" @default.
- W3004915898 creator A5025608430 @default.
- W3004915898 creator A5041474007 @default.
- W3004915898 creator A5043723479 @default.
- W3004915898 creator A5048331793 @default.
- W3004915898 creator A5052925013 @default.
- W3004915898 creator A5053602981 @default.
- W3004915898 creator A5054723357 @default.
- W3004915898 creator A5055686899 @default.
- W3004915898 creator A5055824335 @default.
- W3004915898 creator A5057146350 @default.
- W3004915898 creator A5064115609 @default.
- W3004915898 creator A5079683086 @default.
- W3004915898 creator A5081735541 @default.
- W3004915898 creator A5090448050 @default.
- W3004915898 creator A5090718807 @default.
- W3004915898 date "2020-02-10" @default.
- W3004915898 modified "2023-09-24" @default.
- W3004915898 title "A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab." @default.
- W3004915898 doi "https://doi.org/10.1200/jco.2020.38.5_suppl.79" @default.
- W3004915898 hasPublicationYear "2020" @default.
- W3004915898 type Work @default.
- W3004915898 sameAs 3004915898 @default.
- W3004915898 citedByCount "2" @default.
- W3004915898 countsByYear W30049158982022 @default.
- W3004915898 crossrefType "journal-article" @default.
- W3004915898 hasAuthorship W3004915898A5025608430 @default.
- W3004915898 hasAuthorship W3004915898A5041474007 @default.
- W3004915898 hasAuthorship W3004915898A5043723479 @default.
- W3004915898 hasAuthorship W3004915898A5048331793 @default.
- W3004915898 hasAuthorship W3004915898A5052925013 @default.
- W3004915898 hasAuthorship W3004915898A5053602981 @default.
- W3004915898 hasAuthorship W3004915898A5054723357 @default.
- W3004915898 hasAuthorship W3004915898A5055686899 @default.
- W3004915898 hasAuthorship W3004915898A5055824335 @default.
- W3004915898 hasAuthorship W3004915898A5057146350 @default.
- W3004915898 hasAuthorship W3004915898A5064115609 @default.
- W3004915898 hasAuthorship W3004915898A5079683086 @default.
- W3004915898 hasAuthorship W3004915898A5081735541 @default.
- W3004915898 hasAuthorship W3004915898A5090448050 @default.
- W3004915898 hasAuthorship W3004915898A5090718807 @default.
- W3004915898 hasConcept C121332964 @default.
- W3004915898 hasConcept C121608353 @default.
- W3004915898 hasConcept C126322002 @default.
- W3004915898 hasConcept C142424586 @default.
- W3004915898 hasConcept C143998085 @default.
- W3004915898 hasConcept C2777701055 @default.
- W3004915898 hasConcept C2780030458 @default.
- W3004915898 hasConcept C2908647359 @default.
- W3004915898 hasConcept C71924100 @default.
- W3004915898 hasConcept C87355193 @default.
- W3004915898 hasConcept C90924648 @default.
- W3004915898 hasConcept C99454951 @default.
- W3004915898 hasConceptScore W3004915898C121332964 @default.
- W3004915898 hasConceptScore W3004915898C121608353 @default.
- W3004915898 hasConceptScore W3004915898C126322002 @default.
- W3004915898 hasConceptScore W3004915898C142424586 @default.
- W3004915898 hasConceptScore W3004915898C143998085 @default.
- W3004915898 hasConceptScore W3004915898C2777701055 @default.
- W3004915898 hasConceptScore W3004915898C2780030458 @default.
- W3004915898 hasConceptScore W3004915898C2908647359 @default.
- W3004915898 hasConceptScore W3004915898C71924100 @default.
- W3004915898 hasConceptScore W3004915898C87355193 @default.
- W3004915898 hasConceptScore W3004915898C90924648 @default.
- W3004915898 hasConceptScore W3004915898C99454951 @default.
- W3004915898 hasIssue "5_suppl" @default.
- W3004915898 hasLocation W30049158981 @default.
- W3004915898 hasOpenAccess W3004915898 @default.
- W3004915898 hasPrimaryLocation W30049158981 @default.
- W3004915898 hasRelatedWork W2351796763 @default.
- W3004915898 hasRelatedWork W2351985199 @default.
- W3004915898 hasRelatedWork W2403502999 @default.
- W3004915898 hasRelatedWork W2478002927 @default.
- W3004915898 hasRelatedWork W2567738959 @default.
- W3004915898 hasRelatedWork W2914827752 @default.
- W3004915898 hasRelatedWork W2923882796 @default.
- W3004915898 hasRelatedWork W2947988614 @default.
- W3004915898 hasRelatedWork W4297834875 @default.
- W3004915898 hasRelatedWork W4366141624 @default.
- W3004915898 hasVolume "38" @default.
- W3004915898 isParatext "false" @default.
- W3004915898 isRetracted "false" @default.
- W3004915898 magId "3004915898" @default.
- W3004915898 workType "article" @default.